Once sentiment is shattered, it's hard to recover, which is...

Once sentiment is shattered, it's hard to recover, which is particularly the case for a spec bio stock. Those who would sell at today's price are mostly daytraders or shorters, only very few are real investors in need of cash. In fact all the major shareholders are deeply underwater on this stock and there is no point to sell to end their longstanding misery at the current pitifully low price and a few of them have ever been net buyers to average down.

Undoubtedly, the acquisition of Yale's new innovation gives Patrys a strong position in biotech IP market. Would the next step be that the company also gains a good position in capital market?